beta Amyloid Antibody (Georgetown U. patent anti-Amyloid Beta) [Biotin]

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28836B

Recombinant Monoclonal Antibody
Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Human

Applications

ELISA, Flow Cytometry, Functional

Label

Biotin

Antibody Source

Recombinant Monoclonal Human IgG1 Clone # Georgetown U. patent anti-Amyloid Beta

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

View all Amyloid beta Antibodies »

Product Specifications

Immunogen

Amyloid Beta

Clonality

Monoclonal

Host

Human

Isotype

IgG1

Applications

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Functional

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

PBS

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: Amyloid beta

Beta amyloid, also known as Abeta, is a peptide that varies in length from 39 to 43 amino acids and is processed from the transmembrane protein amyloid precursor protein (APP) by beta-secretase (BACE-1) and gamma-secretase. Beta amyloid [1-40], beta amyloid [1-42], and beta amyloid [1-43] peptides result from cleavage of APP after residues 40, 42, and 43, respectively. The aggregation of beta amyloid monomers produces insoluble oligomers and protofibrils. The longer "stickier" forms of beta amyloid, particularly ABeta42, are known as the main component of amyloid plaques, which are deposits (senile plaques or neuritic plaques) found in the brains of patients with Alzheimer's disease (AD) (1,2). Research indicates that intraneuronal beta amyloid accumulation may be an important proximal neurotoxic event in the pathogenesis of Alzheimer's disease. Abeta deposits have also been reported in the hearts of AD patients (3).

Pyroglutamate amyloid beta peptides (pGlu-Abeta) are N-terminal truncations in which the N-terminal glutamate is cyclized to pyroglutamate resulting in pGlu-Abeta (3-40/42 and 11-40/42) (4). This pyrE modification may have a greater propensity to aggregate under physiological conditions and has been implicated as the molecular species responsible for seeding larger oligomers of amyloid beta.

References

1. Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, Xu HE. (2017) Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin. 38(9):1205-1235. PMID: 28713158

2. De-Paula VJ1, Radanovic M, Diniz BS, Forlenza OV. (2012) Alzheimer's disease. Subcell Biochem. 65:329-52. PMID: 23225010

3. Schaich CL, Maurer MS, Nadkarni NK. (2019) Amyloidosis of the Brain and Heart: Two Sides of the Same Coin? JACC Heart Fail. 7(2):129-131. PMID: 30704604

4. He W, Barrow CJ. (1999) The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. Biochemistry. 38(33):10871-7. PMID: 10451383

Alternate Names

Abeta, beta-Amyloid Peptide

Gene Symbol

APP

Additional Amyloid beta Products

Product Documents

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.